SRC inhibitor saracatinib enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

被引：0
|
作者：
Lu, Fei-Teng [1 ]
Luo, Fan [1 ]
Qiu, Miao-Zhen [1 ]
Cao, Jia-Xin [1 ]
Luo, Qiu-Yun [1 ]
Yang, Da-Jun [2 ]
Zhao, Hong-Yun [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ascentage Pharma Suzhou Co Ltd, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6094
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Significance of the Expression of PD-L1/PD-1 by Tumoral and Immune Cells in Non-Small Cell Lung Cancer.
    Ortiz-Villalon, C.
    De Petris, L.
    Kis, L.
    Yoshikawa, A.
    Ngoc, H.
    Roden, A.
    Fukuoka, J.
    Montero, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S948 - S948
  • [32] Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
    Jiabei He
    Ying Hu
    Mingming Hu
    Baolan Li
    Scientific Reports, 5
  • [33] Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Hersom, Maria
    Jorgensen, Jan T.
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 9 - 16
  • [34] Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer
    Li, Li
    Xu, Chunhua
    Wang, Wei
    Zhang, Qian
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [35] Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
    Cabezon-Gutierrez, Luis
    Custodio-Cabello, Sara
    Palka-Kotlowska, Magda
    Alonso-Viteri, Soledad
    Khosravi-Shahi, Parham
    CLINICAL LUNG CANCER, 2021, 22 (05) : 381 - 389
  • [36] PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
    Luo, Min
    Xia, Yuhui
    Wang, Fang
    Zhang, Hong
    Su, Danting
    Su, Chaoyue
    Yang, Chuan
    Wu, Shaocong
    An, Sainan
    Lin, Suxia
    Fu, Liwu
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (10) : 3120 - 3133
  • [37] PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
    Min Luo
    Yuhui Xia
    Fang Wang
    Hong Zhang
    Danting Su
    Chaoyue Su
    Chuan Yang
    Shaocong Wu
    Sainan An
    Suxia Lin
    Liwu Fu
    Acta Pharmaceutica Sinica B, 2021, 11 (10) : 3120 - 3133
  • [38] A Meta-Analysis of PD-L1 Expression as a Biomarker of PD-1 Blockade in Advanced Non-Small Cell Lung Cancer
    Man, J.
    Gebski, V.
    Mulvey, A.
    Hui, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2001 - S2002
  • [39] PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
    Moradi, Samaneh
    Sarikhani, Pedram
    Albadr, Rafid Jihad
    Taher, Waam Mohammed
    Alwan, Mariem
    Jawad, Mahmood Jasem
    Mushtaq, Hiba
    Vakilzadehian, Niyousha
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [40] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Kuska, Katarzyna
    Skalniak, Lukasz
    Grudnik, Przemyslaw
    Musielak, Bogdan
    Plewka, Jacek
    Kocik, Justyna
    Stec, Malgorzata
    Weglarczyk, Kazimierz
    Sala, Dominik
    Wladyka, Benedykt
    Siedlar, Maciej
    Holak, Tad A.
    Dubin, Grzegorz
    ADVANCED THERAPEUTICS, 2021, 4 (02)
12345